Payment overview · 2025
General Payments
$4,592.25
117 reported records · 23 companies
Healthcare provider profile · identity verified
David H. Lehman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · SACRAMENTO, CA · NPI 1255425724
Verified facts
What the public records show
CMS Open Payments records show David H. Lehman, M.D. received $4,592.25 in general payments during 2025 across 117 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Eliquis, Farxiga, Jardiance, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Xarelto by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $565.55 | 12.3% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $484.01 | 10.5% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $402.17 | 8.8% | 9 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $397.71 | 8.7% | 16 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $329.79 | 7.2% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $242.72 | 5.3% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $233.12 | 5.1% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $217.35 | 4.7% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $202.67 | 4.4% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $202.61 | 4.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $166.69 | 3.6% | 7 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $158.70 | 3.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $131.24 | 2.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 2.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $122.31 | 2.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $109.02 | 2.4% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $97.81 | 2.1% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $97.73 | 2.1% | 8 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $95.18 | 2.1% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $72.68 | 1.6% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $71.32 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.70 | 1.2% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $13.17 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,459.78 | 114 |
| Education | $132.47 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc, Janssen Scientific Affairs, LLC | $508.69 | 18 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $329.79 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $282.10 | 4 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $233.12 | 7 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $222.84 | 2 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $222.74 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $202.61 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $184.93 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $158.70 | 3 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $145.86 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $131.24 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $127.01 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $122.31 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $121.36 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.93 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $117.89 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $117.44 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $109.02 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $97.73 | 8 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $95.18 | 4 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $87.54 | 5 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $85.23 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $72.68 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $71.32 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $69.79 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $51.77 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.63 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $33.57 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $30.95 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $8.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 236 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
61 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 714 | 188 |
| Amlodipine Besylate | Amlodipine Besylate | 686 | 179 |
| Levothyroxine Sodium | Levothyroxine Sodium | 489 | 108 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 335 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 94 |
| Omeprazole | Omeprazole | 299 | 87 |
| Alprazolam | Alprazolam | 267 | 44 |
| Eliquis | Apixaban | 236 | 57 |
| Gabapentin | Gabapentin | 225 | 75 |
| Simvastatin | Simvastatin | 212 | 57 |
| Alendronate Sodium | Alendronate Sodium | 207 | 55 |
| Irbesartan | Irbesartan | 196 | 60 |
| Ezetimibe | Ezetimibe | 180 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 177 | 37 |
| Finasteride | Finasteride | 170 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 52 |
| Carvedilol | Carvedilol | 155 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 43 |
| Potassium Chloride | Potassium Chloride | 145 | 42 |
| Famotidine | Famotidine | 139 | 47 |
| Sertraline Hcl | Sertraline Hcl | 134 | 31 |
| Trazodone Hcl | Trazodone Hcl | 128 | 32 |
| Meloxicam | Meloxicam | 127 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 31 |
| Prednisone | Prednisone | 117 | 47 |
| Lisinopril | Lisinopril | 114 | 34 |
| Donepezil Hcl | Donepezil Hcl | 112 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 108 | 40 |
| Jardiance | Empagliflozin | 107 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 13 |
| Myrbetriq | Mirabegron | 106 | 28 |
| Losartan Potassium | Losartan Potassium | 104 | 27 |
| Montelukast Sodium | Montelukast Sodium | 103 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 19 |
| Lorazepam | Lorazepam | 92 | 21 |
| Temazepam | Temazepam | 92 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 21 |
| Spironolactone | Spironolactone | 86 | 31 |
| Bupropion Xl | Bupropion Hcl | 84 | 20 |
| Mirtazapine | Mirtazapine | 84 | 26 |
| Metformin Hcl | Metformin Hcl | 83 | 23 |
| Tramadol Hcl | Tramadol Hcl | 83 | 26 |
| Pregabalin | Pregabalin | 80 | 23 |
| Torsemide | Torsemide | 80 | 31 |
| Allopurinol | Allopurinol | 79 | 23 |
| Cefdinir | Cefdinir | 79 | 64 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 79 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 41 |
| Celecoxib | Celecoxib | 74 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 24 |
| Cefuroxime | Cefuroxime Axetil | 66 | 44 |
| Ibuprofen | Ibuprofen | 66 | 25 |
| Ozempic | Semaglutide | 66 | 15 |
| Midodrine Hcl | Midodrine Hcl | 62 | 12 |
| Chlorthalidone | Chlorthalidone | 61 | 19 |
| Paxlovid | Nirmatrelvir/Ritonavir | 61 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 21 |
| Xarelto | Rivaroxaban | 61 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 17 |
| Divalproex Sodium | Divalproex Sodium | 60 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 60 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 58 | 26 |
| Metformin Hcl Er | Metformin Hcl | 58 | 19 |
| Furosemide | Furosemide | 56 | 23 |
| Hydromorphone Hcl | Hydromorphone Hcl | 56 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 12 |
| Ketoconazole | Ketoconazole | 55 | 26 |
| Cephalexin | Cephalexin | 54 | 44 |
| Diazepam | Diazepam | 54 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 11 |
| Telmisartan | Telmisartan | 52 | 16 |
| Baclofen | Baclofen | 50 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 36 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 45 | 39 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 15 |
| Nystatin | Nystatin | 40 | 19 |
| Acyclovir | Acyclovir | 39 | 18 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 39 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Modafinil | Modafinil | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 16 |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Estradiol | Estradiol | 30 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 11 |
| Methocarbamol | Methocarbamol | 30 | 11 |
| Amoxicillin | Amoxicillin | 29 | 22 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 18 |
| Lactulose | Lactulose | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Silodosin | Silodosin | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 13 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Minoxidil | Minoxidil | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Belsomra | Suvorexant | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Klor-Con 10 | Potassium Chloride | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Leflunomide | Leflunomide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Actemra Actpen | Tocilizumab | 19 | suppressed |
| Hydroxyurea | Hydroxyurea | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Rasagiline Mesylate | Rasagiline Mesylate | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | 16 |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Ursodiol | Ursodiol | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Armodafinil | Armodafinil | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Relistor | Methylnaltrexone Bromide | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Benlysta | Belimumab | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Ativan | Lorazepam | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,592.25 · 117 records | AstraZeneca Pharmaceuticals LP | ACTHAR, AIRSUPRA, AREXVY, BENLYSTA, BREZTRI, Bimzelx, COSENTYX, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, LUPKYNIS, NURTEC ODT, OFEV, OTEZLA, Ohtuvayre, Ozempic, RINVOQ, Rybelsus, SAPHNELO, SKYRIZI, SMARTVEST, TAVNEOS, TRELEGY ELLIPTA, TREMFYA, TZIELD, VYNDAQEL, ZENPEP, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error